“As leaders, we have a responsibility to come together to impact cancer. Colorectal cancer is one of the most preventable and treatable cancers when diagnosed
ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison to its board of
FDA’s Decision Forthcoming for Innovative Test with Agency’s Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 / — Geneoscopy, Inc., a life sciences company focused
Colorectal Cancer and Advanced Adenoma Sensitivity Results are the Highest Reported from any Prospective Pivotal Study for a Noninvasive Screening Test Innovative RNA Biomarker Screening
New look matches focus on transforming GI health ST. LOUIS, MISSOURI (October 3, 2022) | Geneoscopy today announced a corporate rebrand and launch. The rebranding
Trial Enrollment Over Indexes in Traditionally Under-Represented Black Community ST. LOUIS, Aug. 23, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests
ST. LOUIS, MISSOURI (JULY 19, 2022) | Earlier this year, President Joe Biden announced plans to reignite the Cancer Moonshot with renewed leadership and new ambitious
ST. LOUIS, June 21, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced the formation of
Data at 2022 Digestive Disease Week Meeting Also Shows RNA-FIT Test to Be Cost-Effective ST. LOUIS, May 23, 2022 /PRNewswire/ — Geneoscopy Inc., a life sciences company focused on
